FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626024150> ?p ?o ?g. }

• W2626024150 abstract "The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics (genetically-engineered proteins that usually are derived from human genes) for inflammatory myositis has been reported. In 2011-2016 we investigated our collective experience of biologics in JDM through the Childhood Arthritis and Rheumatology Research Alliance (CARRA).The JDM biologic study group developed a survey on the CARRA member experience using biologics for Juvenile DM utilizing Delphi consensus methods in 2011-2012. The survey was completed online by the CARRA members interested in JDM in 2012. A second survey was similarly developed that provided more opportunity to describe their experiences with biologics in JDM in detail and was completed by CARRA members in Feb 2013. During three CARRA meetings in 2013-2015, nominal group techniques were used for achieving consensus on the current choices of biologic drugs. A final survey was performed at the 2016 CARRA meeting.One hundred and five of a potential 231 pediatric rheumatologists (42%) responded to the first survey in 2012. Thirty-five of 90 had never used a biologic for Juvenile DM at that time. Fifty-five of 91 (denominators vary) had used biologics for JDM in their practice with 32%, 5%, and 4% using rituximab, etanercept, and infliximab, respectively, and 17% having used more than one of the three drugs. Ten percent used a biologic as monotherapy, 19% a biologic in combination with methotrexate (mtx), 52% a biologic in combination with mtx and corticosteroids, 42% a combination of a biologic, mtx, corticosteroids (steroids), and an immunosuppressive drug, and 43% a combination of a biologic, IVIG and mtx. The results of the second survey supported these findings in considerably more detail with multiple combinations of drugs used with biologics and supported the use of rituximab, abatacept, anti-TNFα drugs, and tocilizumab in that order. One hundred percent recommended that CARRA continue studying biologics for JDM. The CARRA meeting survey in 2016 again supported the study and use of these four biologic drug groups.Our CARRA JDM biologic work group developed and performed three surveys demonstrating that pediatric rheumatologists in North America have been using multiple biologics for refractory JDM in numerous scenarios from 2011 to 2016. These survey results and our consensus meetings determined our choice of four biologic therapies (rituximab, abatacept, tocilizumab and anti-TNFα drugs) to consider for refractory JDM treatment when indicated and to evaluate for comparative effectiveness and safety in the future. Significance and Innovations This is the first report that provides a substantial clinical experience of a large group of pediatric rheumatologists with biologics for refractory JDM over five years. This experience with biologic therapies for refractory JDM may aid pediatric rheumatologists in the current treatment of these children and form a basis for further clinical research into the comparative effectiveness and safety of biologics for refractory JDM." @default.
• W2626024150 created "2017-06-23" @default.
• W2626024150 creator A5000223102 @default.
• W2626024150 creator A5002183437 @default.
• W2626024150 creator A5003487438 @default.
• W2626024150 creator A5005252557 @default.
• W2626024150 creator A5006685405 @default.
• W2626024150 creator A5009088784 @default.
• W2626024150 creator A5013019528 @default.
• W2626024150 creator A5013489214 @default.
• W2626024150 creator A5015352382 @default.
• W2626024150 creator A5018854057 @default.
• W2626024150 creator A5025175082 @default.
• W2626024150 creator A5025986368 @default.
• W2626024150 creator A5026927697 @default.
• W2626024150 creator A5029058963 @default.
• W2626024150 creator A5035430191 @default.
• W2626024150 creator A5041917650 @default.
• W2626024150 creator A5042979209 @default.
• W2626024150 creator A5043524804 @default.
• W2626024150 creator A5043920167 @default.
• W2626024150 creator A5045735702 @default.
• W2626024150 creator A5050791945 @default.
• W2626024150 creator A5051416330 @default.
• W2626024150 creator A5054460357 @default.
• W2626024150 creator A5059855682 @default.
• W2626024150 creator A5063405234 @default.
• W2626024150 creator A5063503884 @default.
• W2626024150 creator A5066782781 @default.
• W2626024150 creator A5072820878 @default.
• W2626024150 creator A5075986078 @default.
• W2626024150 creator A5079325843 @default.
• W2626024150 creator A5079551133 @default.
• W2626024150 creator A5083490131 @default.
• W2626024150 creator A5089259012 @default.
• W2626024150 creator A5090678049 @default.
• W2626024150 creator A5091047529 @default.
• W2626024150 creator A5091692499 @default.
• W2626024150 creator A5091884614 @default.
• W2626024150 date "2017-06-13" @default.
• W2626024150 modified "2023-10-16" @default.
• W2626024150 title "Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America" @default.
• W2626024150 cites W14437623 @default.
• W2626024150 cites W1508545409 @default.
• W2626024150 cites W1835542098 @default.
• W2626024150 cites W1972863848 @default.
• W2626024150 cites W1976995552 @default.
• W2626024150 cites W1984338880 @default.
• W2626024150 cites W1986992328 @default.
• W2626024150 cites W1995485558 @default.
• W2626024150 cites W1996642424 @default.
• W2626024150 cites W1996838316 @default.
• W2626024150 cites W2012240762 @default.
• W2626024150 cites W2013603536 @default.
• W2626024150 cites W2021579922 @default.
• W2626024150 cites W2023525944 @default.
• W2626024150 cites W2026336484 @default.
• W2626024150 cites W2036119782 @default.
• W2626024150 cites W2036753188 @default.
• W2626024150 cites W2038295742 @default.
• W2626024150 cites W2049268737 @default.
• W2626024150 cites W2057350030 @default.
• W2626024150 cites W2064304125 @default.
• W2626024150 cites W2064372459 @default.
• W2626024150 cites W2064892481 @default.
• W2626024150 cites W2069792536 @default.
• W2626024150 cites W207060674 @default.
• W2626024150 cites W2076417190 @default.
• W2626024150 cites W2079824024 @default.
• W2626024150 cites W2086833456 @default.
• W2626024150 cites W2095568073 @default.
• W2626024150 cites W2098488998 @default.
• W2626024150 cites W2106302854 @default.
• W2626024150 cites W2107843884 @default.
• W2626024150 cites W2109049456 @default.
• W2626024150 cites W2116156517 @default.
• W2626024150 cites W2125816072 @default.
• W2626024150 cites W2127444386 @default.
• W2626024150 cites W2137816646 @default.
• W2626024150 cites W2143363615 @default.
• W2626024150 cites W2165056158 @default.
• W2626024150 cites W2168366128 @default.
• W2626024150 cites W2169638076 @default.
• W2626024150 cites W2170150311 @default.
• W2626024150 cites W2171246731 @default.
• W2626024150 cites W2274424505 @default.
• W2626024150 cites W2314495923 @default.
• W2626024150 cites W2329505338 @default.
• W2626024150 cites W2408220346 @default.
• W2626024150 cites W2417541207 @default.
• W2626024150 cites W2418875512 @default.
• W2626024150 cites W4210986073 @default.
• W2626024150 cites W4236000211 @default.
• W2626024150 doi "https://doi.org/10.1186/s12969-017-0174-0" @default.
• W2626024150 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5470177" @default.
• W2626024150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28610606" @default.
• W2626024150 hasPublicationYear "2017" @default.
• W2626024150 type Work @default.
• W2626024150 sameAs 2626024150 @default.
• W2626024150 citedByCount "36" @default.

• next